Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous golimumab in active psoriatic arthritis (Phase 3, randomized, placebo-controlled)
2014-000242-30Phase 3Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Golimumab IV 2 mg/kg with Placebo IV (2 arms). Primary endpoint: ACR20 response at week 14. Started Oct 2014; status: completed.
02
Drugs
golimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2014-000242-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000242-30.